Alto Neuroscience (NYSE:ANRO) Stock Price Down 6% – Here’s Why

Alto Neuroscience, Inc. (NYSE:ANRO) traded down 6% during mid-day trading on Friday . The company traded as low as $16.90 and last traded at $16.74. 59,931 shares were traded during trading, a decline of 86% from the average session volume of 425,848 shares. The stock had previously closed at $17.80.

Analyst Ratings Changes

ANRO has been the topic of a number of analyst reports. BTIG Research initiated coverage on shares of Alto Neuroscience in a report on Monday, November 17th. They issued a “buy” rating and a $27.00 target price on the stock. Wall Street Zen upgraded Alto Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday. Robert W. Baird increased their price objective on shares of Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Finally, Chardan Capital raised Alto Neuroscience to a “strong-buy” rating in a research report on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Alto Neuroscience has an average rating of “Moderate Buy” and a consensus price target of $23.83.

Alto Neuroscience Trading Down 6.7%

The firm’s 50 day moving average is $14.78 and its 200 day moving average is $7.65. The company has a debt-to-equity ratio of 0.20, a current ratio of 15.42 and a quick ratio of 15.42. The company has a market cap of $515.98 million, a PE ratio of -7.30 and a beta of 2.76.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.14. On average, equities analysts anticipate that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can bought a new stake in Alto Neuroscience during the second quarter worth about $25,000. Ground Swell Capital LLC bought a new position in shares of Alto Neuroscience during the 2nd quarter valued at about $27,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Alto Neuroscience during the 2nd quarter valued at about $33,000. AlphaCore Capital LLC lifted its position in Alto Neuroscience by 100.0% in the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after buying an additional 10,000 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new stake in Alto Neuroscience during the first quarter valued at about $52,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.